JP2021078504A5 - - Google Patents

Download PDF

Info

Publication number
JP2021078504A5
JP2021078504A5 JP2021005834A JP2021005834A JP2021078504A5 JP 2021078504 A5 JP2021078504 A5 JP 2021078504A5 JP 2021005834 A JP2021005834 A JP 2021005834A JP 2021005834 A JP2021005834 A JP 2021005834A JP 2021078504 A5 JP2021078504 A5 JP 2021078504A5
Authority
JP
Japan
Prior art keywords
seq
identity
composition according
clostridium
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021005834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021078504A (ja
JP7165218B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021078504A publication Critical patent/JP2021078504A/ja
Publication of JP2021078504A5 publication Critical patent/JP2021078504A5/ja
Priority to JP2022168855A priority Critical patent/JP7503273B2/ja
Application granted granted Critical
Publication of JP7165218B2 publication Critical patent/JP7165218B2/ja
Priority to JP2024087782A priority patent/JP2024129016A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021005834A 2011-12-01 2021-01-18 制御性t細胞の増殖または集積を誘導するヒト由来細菌 Active JP7165218B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022168855A JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2024087782A JP2024129016A (ja) 2011-12-01 2024-05-30 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161565976P 2011-12-01 2011-12-01
US61/565,976 2011-12-01
US201261607360P 2012-03-06 2012-03-06
US61/607,360 2012-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019038453A Division JP7097838B2 (ja) 2011-12-01 2019-03-04 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022168855A Division JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Publications (3)

Publication Number Publication Date
JP2021078504A JP2021078504A (ja) 2021-05-27
JP2021078504A5 true JP2021078504A5 (https=) 2022-01-06
JP7165218B2 JP7165218B2 (ja) 2022-11-02

Family

ID=48535050

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014526308A Active JP6306507B2 (ja) 2011-12-01 2012-11-29 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2017213526A Active JP6492151B2 (ja) 2011-12-01 2017-11-06 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2019038453A Active JP7097838B2 (ja) 2011-12-01 2019-03-04 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2021005834A Active JP7165218B2 (ja) 2011-12-01 2021-01-18 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2022168855A Active JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2024087782A Pending JP2024129016A (ja) 2011-12-01 2024-05-30 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2014526308A Active JP6306507B2 (ja) 2011-12-01 2012-11-29 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2017213526A Active JP6492151B2 (ja) 2011-12-01 2017-11-06 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2019038453A Active JP7097838B2 (ja) 2011-12-01 2019-03-04 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022168855A Active JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP2024087782A Pending JP2024129016A (ja) 2011-12-01 2024-05-30 制御性t細胞の増殖または集積を誘導するヒト由来細菌

Country Status (10)

Country Link
US (11) US10238694B2 (https=)
EP (4) EP3978598B1 (https=)
JP (6) JP6306507B2 (https=)
CN (3) CN116942833A (https=)
CA (1) CA2892588A1 (https=)
DK (2) DK3978598T3 (https=)
ES (2) ES2993669T3 (https=)
FI (2) FI3978598T3 (https=)
HK (1) HK1204008A1 (https=)
WO (1) WO2013080561A1 (https=)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
CA2813606C (en) 2010-10-07 2019-01-22 Sarkis K. Mazmanian Probiotic therapies for autism
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2993669T3 (en) * 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
AU2015244700B2 (en) * 2014-04-10 2020-08-27 Riken Compositions and methods for induction of Th17 cells
US20150322176A1 (en) * 2014-04-16 2015-11-12 University Of Guelph Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof
US20170087196A1 (en) * 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016086161A1 (en) * 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
EP3242673A1 (en) * 2015-01-07 2017-11-15 Ecole Polytechnique Fédérale de Lausanne (EPFL) Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性t細胞の誘導
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
PY1639434A (es) 2015-06-25 2018-08-01 Ascus Biosciences Inc Procedimientos, aparatos y sistemas para el analisis de cepas de microorganismos provinientes de comunidades complejas y heterogenas. prediccion e identificacion de relaciones..//.
CA3006057A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues
CN115252650A (zh) * 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3380108T3 (pl) * 2015-11-24 2023-03-27 Seres Therapeutics, Inc. Zaprojektowane kompozycje bakteryjne
MX392304B (es) 2016-01-07 2025-03-24 Native Microbials Inc Métodos para mejorar la producción de leche mediante la administración de consorcios microbianos.
JP6675752B2 (ja) * 2016-02-23 2020-04-01 国立大学法人佐賀大学 腸内Blautia coccoides増殖刺激剤
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
EP3429604A1 (en) 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017160944A2 (en) 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
EP3850953B1 (en) 2016-06-10 2023-11-01 N.V. Nutricia Nutrition to reduce the risk of allergy
CA3226196A1 (en) * 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10722600B2 (en) 2016-06-17 2020-07-28 New York University Methods and compositions for treating cancer
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
JP6408092B2 (ja) * 2016-08-29 2018-10-17 国立大学法人 東京大学 糞便微生物叢を含む組成物
KR102708641B1 (ko) 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018081550A1 (en) 2016-10-28 2018-05-03 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
US12285475B2 (en) * 2016-11-01 2025-04-29 Keio University Bacterium capable of inducing TH1 cells
WO2018094190A2 (en) * 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018107365A1 (zh) * 2016-12-13 2018-06-21 深圳华大基因研究院 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
RU2761873C2 (ru) * 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
CA3048246A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
JP2020506968A (ja) * 2017-02-07 2020-03-05 カリフォルニア インスティチュート オブ テクノロジー ハンチントン病およびレット症候群における腸内微生物叢の調節
US10596206B1 (en) 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
UY37708A (es) 2017-04-28 2018-10-31 Ascus Biosciences Inc Métodos para complementar dietas con alto consumo de granos y/o alto valor energético en rumiantes, mediante la administración de un bioensamble sintético de microbios, o cepas purificadas de los mismos
WO2018213262A1 (en) 2017-05-19 2018-11-22 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing listeria monocytogenes infection or colonization
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
AU2018309153A1 (en) * 2017-08-04 2020-03-19 Tarunmeet GUJRAL Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
AU2018313765A1 (en) * 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス, インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
US10507221B2 (en) 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP3706767A4 (en) * 2017-11-09 2021-12-15 Vedanta Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
AU2019217041B2 (en) 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
EP3594321A1 (en) 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
DE102018213030A1 (de) * 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
AU2019321681A1 (en) * 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
WO2020071463A1 (ja) * 2018-10-04 2020-04-09 国立研究開発法人理化学研究所 ILC2を標的としたIgA産生誘導方法
CN113271796A (zh) * 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
US12551515B2 (en) 2018-11-21 2026-02-17 Board Of Regents Of The University Of Texas System Methods and compositions for treating cancer
WO2020234746A1 (en) 2019-05-18 2020-11-26 Janssen Biotech, Inc. Materials and methods for microbiome modulation
EP3999029A4 (en) * 2019-07-17 2023-07-26 University of Utah Research Foundation CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATMENT OF OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
JP2022544369A (ja) * 2019-08-14 2022-10-18 ヴァーヘニンゲン・ウニヴェルシテイト ミオ-イノシトール-プロピオネート経路を含む細菌
WO2021033042A1 (en) 2019-08-16 2021-02-25 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
US20250270498A1 (en) * 2019-08-16 2025-08-28 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
JP2022544615A (ja) 2019-08-16 2022-10-19 ヤンセン バイオテツク,インコーポレーテツド クロストリジウム属細菌の最適化された培養培地
JP2021045097A (ja) * 2019-09-20 2021-03-25 腸内フローラ移植臨床研究株式会社 腸内フローラの健康状態の診断方法及びその利用
US20220409675A1 (en) * 2019-11-22 2022-12-29 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
US20230131960A1 (en) * 2020-03-25 2023-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to treat and prevent diseases caused by enterobacteriae
EP3895710A1 (en) 2020-04-15 2021-10-20 DSM IP Assets B.V. Food and/or feed compositions to manage immune homeostasis
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN115666604A (zh) * 2020-05-21 2023-01-31 超级酿造食品公司 治疗或预防感染的方法
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US12011467B2 (en) 2021-05-18 2024-06-18 J. Craig Venter Institute, Inc. Bacterial formulation
CN116195742B (zh) * 2021-11-30 2024-07-09 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在保护软骨中的应用
US20250025545A1 (en) * 2021-12-02 2025-01-23 Kanagawa Institute Of Industrial Science And Technology Establishment of therapy and diagnosis for allergic diseases through control of immunoglobulin-binding protein
CN114917252A (zh) * 2021-12-29 2022-08-19 慕恩(广州)生物科技有限公司 毛螺菌科微生物菌株、预防和/或治疗肿瘤的药物及应用
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069074D1 (en) 1979-11-16 1984-10-04 Sterosynt Ltd 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
ATE407700T1 (de) 1996-03-20 2008-09-15 Univ New South Wales Veränderung der mikrobenflora im verdauungstrakt
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP2001112485A (ja) 1999-10-19 2001-04-24 Yakult Honsha Co Ltd 腸内細菌用プライマー及び該プライマーを用いた検出方法
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
GB0220809D0 (en) * 2002-09-06 2002-10-16 Univ College Of London Immune modulator
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
JP2005124495A (ja) 2003-10-24 2005-05-19 Yakult Honsha Co Ltd ヒト腸内細菌検出用プライマー
EP1749538A4 (en) 2004-03-31 2009-11-11 Kirin Pharma Kk METHOD FOR DETERMINING THE DIFFERENTIATION OF REGULATORY T CELLS AND THEIR PROLIFERATION WITH GPI ANCHOR PROTEIN AGONISTS AND MEDICINAL COMPOSITION THEREFOR
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
KR101260533B1 (ko) 2005-03-03 2013-05-06 가부시키가이샤 메이지 면역기능 조정제
CU23581A1 (es) * 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
EP1964570B1 (de) 2007-03-02 2012-11-21 Protectimmun GmbH Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
EP1974743A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CN101310730A (zh) 2007-05-27 2008-11-26 青岛东海药业有限公司 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用
JP2009084215A (ja) 2007-09-28 2009-04-23 Nippon Paper Chemicals Co Ltd 炎症性腸疾患予防・治療剤
WO2009050486A2 (en) 2007-10-19 2009-04-23 The University Of Surrey Peptide manipulators of regulatory t cell activity
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CN101496819A (zh) 2008-01-31 2009-08-05 青岛东海药业有限公司 真杆菌、梭菌制剂及其应用
KR100913405B1 (ko) 2008-03-25 2009-08-21 광주과학기술원 Th2-매개 면역 질환의 예방 또는 치료용 조성물
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
JP2010129134A (ja) 2008-11-28 2010-06-10 Pulstec Industrial Co Ltd ホログラム記録装置及びホログラム再生装置
EP3073263B1 (en) 2009-02-13 2020-04-29 The Regents of the University of California Device, composition and method for tissue-based diagnosis
GB0903016D0 (en) 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
US20100275282A1 (en) 2009-04-23 2010-10-28 Round June L Methods and systems for identifying immunomodulatory substances
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
ES2610829T3 (es) 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
JP5578375B2 (ja) * 2010-02-10 2014-08-27 日環科学株式会社 好熱性微生物を用いた混合物、溶解液、及び医薬品
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
ES2388662B1 (es) 2010-11-10 2014-04-11 Consejo Superior De Investigaciones Científicas (Csic) Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína.
US20120279149A1 (en) * 2011-05-04 2012-11-08 Sebastian George Quinn System and device for utilization of energy in buildings
US20140171339A1 (en) * 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2993669T3 (en) * 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2922555A4 (en) 2012-11-26 2016-06-15 Borody Thomas J COMPOSITIONS FOR THE RESTORATION OF A FÄKALBIOZÖNOSE AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
WO2015006355A2 (en) * 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
AU2015244700B2 (en) 2014-04-10 2020-08-27 Riken Compositions and methods for induction of Th17 cells
US10159109B2 (en) 2014-06-27 2018-12-18 Telefonaktiebolaget Lm Ericsson (Publ) System and method for supporting time-sensitive services in a communication network
WO2016003536A1 (en) 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016194427A1 (ja) 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US9642281B1 (en) * 2015-12-28 2017-05-02 Martas Precision Slide Co., Ltd. Buckle set for sliding rail of industrial rackmount chassis
EP3429604A1 (en) * 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017160944A2 (en) 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
JP6792103B2 (ja) 2016-06-01 2020-11-25 株式会社テックコーポレーション 微細気泡水供給システム
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US12285475B2 (en) 2016-11-01 2025-04-29 Keio University Bacterium capable of inducing TH1 cells
RU2761873C2 (ru) * 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
AU2018313765A1 (en) 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
JP2019046634A (ja) * 2017-08-31 2019-03-22 パナソニックIpマネジメント株式会社 照明システム及びコントローラ
US10507221B2 (en) * 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
AU2019217041B2 (en) 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
AU2019321681A1 (en) 2018-08-17 2021-02-25 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
WO2020234746A1 (en) 2019-05-18 2020-11-26 Janssen Biotech, Inc. Materials and methods for microbiome modulation
EP4362961A1 (en) 2021-06-28 2024-05-08 Vedanta Biosciences, Inc. Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease

Similar Documents

Publication Publication Date Title
JP2021078504A5 (https=)
JP2018039833A5 (https=)
Wang et al. Probiotics to prevent respiratory infections in nursing homes: a pilot randomized controlled trial
Sood et al. The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis
US10925908B2 (en) Method of identifying a biologically-active composition from a biofilm
Meini et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature
Liu et al. Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation
Waki et al. Oral administration of Lactobacillus brevis KB290 to mice alleviates clinical symptoms following influenza virus infection
JP2024129016A5 (https=)
BR112013016690A2 (pt) agente para induzir a produção de ifn, agente imunopotencializador, agente para prevenção ou tratamento de infecção viral, produto comestível ou bebível, método de triagem de bactérias do ácido lático, microrganismo hospedeiro para uma vacina recombinante
Coleman et al. Probiotics in the treatment of otitis media. The past, the present and the future
JP2021501185A5 (https=)
Neau et al. Three novel candidate probiotic strains with prophylactic properties in a murine model of cow's milk allergy
JP2016509003A5 (https=)
CN109715179A (zh) 用于治疗皮肤病症的组合物和方法
Chi et al. Real-time induction of macrophage apoptosis, pyroptosis, and necroptosis by Enterococcus faecalis OG1RF and two root canal isolated strains
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
JP2019500056A5 (https=)
JP2019522649A (ja) 健康な皮膚微生物叢の維持及び/又は回復に対する皮膚科調合剤
JP2020520916A5 (https=)
JP2022501330A5 (https=)
CN119948147A (zh) 巨大芽孢杆菌菌株、其组合物及使用方法
Kang et al. A recombinant Bifidobacterium bifidum BGN4 strain expressing the streptococcal superoxide dismutase gene ameliorates inflammatory bowel disease
Tamura et al. Peptides from rice endosperm protein restrain periodontal bone loss in mouse model of periodontitis
JPWO2020179868A5 (https=)